key: cord-0856040-2bx9ldyy
authors: Ding, Qianqian; Li, Xiaofei
title: A commentary on “Economic evaluation of programs against COVID-19: A systematic review”
date: 2021-02-10
journal: Int J Surg
DOI: 10.1016/j.ijsu.2021.01.015
sha: f4985f48d70962db4de43463b5004912b5e0bb7c
doc_id: 856040
cord_uid: 2bx9ldyy

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. systematic review"

The novel coronavirus SARS-CoV-2 was identified as the causative agent for a series of atypical respiratory diseases in the Hubei Province of Wuhan, China in December of 2019. The disease SARS-CoV-2, termed COVID-19, was officially declared a pandemic by the World Health Organization on March 11, 2020. COVID-19 infection results in diverse symptoms and morbidity depending on individual genetics, ethnicity, age, and geographic location. [1] In severe cases, COVID-19 pathophysiology includes destruction of lung epithelial cells, thrombosis, hypercoagulation, and vascular leak leading to sepsis. These events lead to acute respiratory distress syndrome (ARDS) and subsequent pulmonary fibrosis in patients. [2] Since the initial outbreak, asymptomatic carriers of the virus and related infections have been reported in several studies. In the wake of these findings, it was suspected that asymptomatic and presymptomatic infectivity might have accounted for significant portions of the spread of the disease. If so, prevention and containment of the ongoing epidemic can be challenging, not only in China but also in other countries. Rezapour et al [3] reviewed twenty-six studies to summarize economic evaluation evidence of preventing strategies, programs, and treatments of COVID-19. The results suggested screening tests and social distancing to be cost-effective alternatives in preventing and controlling COVID-19 on a long-time horizon.

Preventive measures are the current strategy to limit the spread of cases. Early screening, diagnosis, isolation, and treatment are necessary to prevent further spread. Preventive strategies are focused on the isolation of patients and careful infection control, including appropriate measures to be adopted during the diagnosis and the provision of clinical care to an infected patient. Social distancing is designed to reduce interactions between people in a broader community, in which individuals may be infectious but have not yet been identified hence not yet isolated. [4] As diseases transmitted by respiratory droplets require a certain proximity of people, social distancing of persons will reduce transmission. Social distancing is particularly useful in settings where community transmission is believed to have occurred, but where the linkages between cases is unclear, and where restrictions placed only on persons known to have been exposed is considered insufficient to prevent further transmission.

The included economic evaluation studies were different vastly based on type of interventions, used methods, setting, perspectives, and populations. For this reason, direct comparing the results of studies was difficult (e.g., preventive and diagnostic procedures, also drug therapies). Further basic and clinical studies are required to determine the best strategies against COVID-19 pandemic.

The following additional information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

There is no conflicts of interest among authors.

This is a commentary, no funding is required.

This is a commentary, no ethical approval is required.

Please enter the name of the registry and the unique identifying number of the study. You can register your research at http://www.researchregistry.com to obtain your UIN if you have not already registered your study. This is mandatory for human studies only. This is a commentary, no UIN is required.

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

The Pathology of Severe COVID-19-Related Lung Damage

Economic evaluation of programs against COVID-19: A systematic review

Social distancing, social justice, and risk during the COVID-19 pandemic

This is a commentary, no ISRCTN is required.

Please specify the contribution of each author to the paper, e.g. study design, data collections, data analysis, writing. Others, who have contributed in other ways should be listed as contributors.Qianqian Ding performs the commentary, Xiaofei Li edits the language.

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

J o u r n a l P r e -p r o o f